

## Highlights of This Issue 1345

### SPECIAL FEATURES

#### Editors' Note

- 1347 **Introducing *New Strategies in...***  
James L. Abbruzzese,  
Alexander M.M. Eggermont, and Eric H. Rubin

#### CCR New Strategies

- 1348 **New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance**  
Brian I. Rini

#### CCR Translations

- 1355 **Does Lapatinib Work against HER2-negative Breast Cancers?**  
Ingrid A. Mayer and Carlos L. Arteaga  
*See article p. 1486*

#### Statistics in Clinical Cancer Research

- 1358 **Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge**  
Irina Ostrovnaya and Colin B. Begg

#### CCR Drug Updates

- 1368 **Everolimus**  
Peter J. Houghton

#### Molecular Pathways

- 1373 **HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy**  
Marcia R. Campbell, Dhara Amin, and Mark M. Moasser
- 1384 **Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward**  
David G. Menter, Richard L. Schilsky, and Raymond N. DuBois

## HUMAN CANCER BIOLOGY

- 1391 **High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Disease-Related Small Bowel Adenocarcinomas**  
Begoña Diosdado, Tineke E. Buffart, Russell Watkins, Beatriz Carvalho, Bauke Ylstra, Marianne Tijssen, Anne S. Bolijn, Fraser Lewis, Karen Maude, Caroline Verbeke, Iris D. Nagtegaal, Heike Grabsch, Chris J.J. Mulder, Phil Quirke, Peter Howdle, and Gerrit A. Meijer
- 1402 **Critical Role of  $G\alpha_{12}$  and  $G\alpha_{13}$  for Human Small Cell Lung Cancer Cell Proliferation *In vitro* and Tumor Growth *In vivo***  
Marius Grzelinski, Olaf Pinkenburg, Thomas Büch, Maike Gold, Stefanie Stohr, Hermann Kalwa, Thomas Gudermann, and Achim Aigner
- 1416 **Association of *TGF- $\beta$ 1* Genetic Variants with HPV16-positive Oropharyngeal Cancer**  
Xiaoxiang Guan, Erich M. Sturgis, Dapeng Lei, Zhensheng Liu, Kristina R. Dahlstrom, Qingyi Wei, and Guojun Li
- 1423 **ZIP4 Regulates Pancreatic Cancer Cell Growth by Activating IL-6/STAT3 Pathway through Zinc Finger Transcription Factor CREB**  
Yuqing Zhang, Uddalak Bharadwaj, Craig D. Logsdon, Changyi Chen, Qizhi Yao, and Min Li
- 1431 **Neuroblastoma Progression Correlates with Downregulation of the Lymphangiogenesis Inhibitor sVEGFR-2**  
Jürgen Becker, Helena Pavlakovic, Fabian Ludewig, Fabiola Wilting, Herbert A. Weich, Romulo Albuquerque, Jayakrishna Ambati, and Jörg Wilting

## CANCER THERAPY: PRECLINICAL

- 1442 **Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy**  
Xin Dong, Jun Guan, John C. English, Julia Flint, John Yee, Kenneth Evans, Nevin Murray, Calum MacAulay, Raymond T. Ng, Peter W. Gout, Wan L. Lam, Janessa Laskin, Victor Ling, Stephen Lam, and Yuzhuo Wang
- 1452 **Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer**  
Stefanie Hammer, Anette Sommer, Iduna Fichtner, Michael Becker, Jana Rolff, Johannes Merk, Ulrich Klar, and Jens Hoffmann
- 1466 **An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity**  
Zachary Hartman, Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, Dong-Wan Kim, Wenle Xia, Neil Spector, Jeffrey Marks, William Barry, Amy Hobeika, Gayathri Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, and Timothy M. Clay
- 1478 **Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma**  
Radhika Iyer, Audrey E. Evans, Xiaoxue Qi, Ruth Ho, Jane E. Minturn, Huaqing Zhao, Naomi Balamuth, John M. Maris, and Garrett M. Brodeur
- 1486 **Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance**  
Alexandra F. Leary, Suzanne Drury, Simone Detre, Sunil Pancholi, Anne Lykkesfeldt, Lesley-Ann Martin, Mitch Dowsett, and Stephen R.D. Johnston
- 1498 **Preclinical Investigation of PEGylated Tumor Necrosis Factor  $\alpha$  in Dogs with Spontaneous Tumors: Phase I Evaluation**  
Douglas H. Thamm, Ilene D. Kurzman, Mike A. Clark, E.J. Ehrhart III, Susan L. Kraft, Daniel L. Gustafson, and David M. Vail

1509

**Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab *In vitro* and *In vivo***  
Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, and Richard S. Finn

1520

**Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma**  
Toshihiko Ishii, Takashi Ishida, Atae Utsunomiya, Atsushi Inagaki, Hiroki Yano, Hirokazu Komatsu, Shinsuke Iida, Kazunori Imada, Takashi Uchiyama, Shiro Akinaga, Kenya Shitara, and Ryuzo Ueda

## IMAGING, DIAGNOSIS, PROGNOSIS

1532

**Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature**  
Katleen De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Eggert, Matthias Fischer, Isabelle Janoueix-Lerosey, Cinzia Lavarino, John M. Maris, Jaume Mora, Akira Nakagawara, André Oberthuer, Miki Ohira, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, and Jo Vandesompele

1542

**Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2- $^{18}\text{F}$ -Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Imaging Biomarkers**  
Craig J. Galbán, Mahaveer S. Bhojani, Kuei C. Lee, Charles R. Meyer, Marcian E. Van Dort, Kyle K. Kuszpit, Robert A. Koeppe, Rajesh Ranga, Bradford A. Moffat, Timothy D. Johnson, Thomas L. Chenevert, Alnawaz Rehemtulla, and Brian D. Ross

1553

**Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer**  
Sarah Minner, Birte Jessen, Lars Stiedenroth, Eike Burandt, Jens Köllermann, Martina Mirlacher, Andreas Erbersdobler, Christian Eichelberg, Margit Fisch, Tim Henrik Brümmendorf, Carsten Bokemeyer, Ronald Simon, Thomas Steuber, Markus Graefen, Hartwig Huland, Guido Sauter, and Thorsten Schlömm

1561 **A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry**  
Mari Mino-Kenudson, Lucian R. Chiriac, Kenny Law, Jason L. Hornick, Neal Lindeman, Eugene J. Mark, David W. Cohen, Bruce E. Johnson, Pasi A. Jänne, A. John Iafrate, and Scott J. Rodig

1572 **Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer**  
Kevin R. Rice, Yongmei Chen, Amina Ali, Eric J. Whitman, Amy Blase, Mona Ibrahim, Sally Elsamamoudi, Stephen Brassell, Bungo Furusato, Norbert Stingle, Isabell A. Sesterhenn, Gyorgy Petrovics, Siobhan Miick, Harry Rittenhouse, Jack Groskopf, David G. McLeod, and Shiv Srivastava

1577 **Melanoma MicroRNA Signature Predicts Post-Recurrence Survival**  
Miguel F. Segura, Ilana Belitskaya-Lévy, Amy E. Rose, Jan Zakrzewski, Avital Gaziel, Douglas Hanniford, Farbod Darvishian, Russell S. Berman, Richard L. Shapiro, Anna C. Pavlick, Iman Osman, and Eva Hernando

1587 **Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab**  
Howard M. Stern, Mary Padilla, Klaus Wagner, Lukas Amler, and Avi Ashkenazi

1597 **IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group**  
Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorn, Pieter Wesseling, Marc Frenay, Cees C. Tijssen, Denis Lacombe, Ahmed Idbaih, Ronald van Marion, Johan M. Kros, Winand N.M. Dinjens, Thierry Gorlia, and Marc Sanson

## CANCER THERAPY: CLINICAL

1605 **Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma *In situ* Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial**  
Nigel J. Bundred, Angela Cramer, Julie Morris, Lorna Renshaw, Kwok-Leung Cheung, Pamela Flint, Rachael Johnson, Oliver Young, Göran Landberg, Sue Grassby, Lorraine Turner, Andrew Baildam, Lester Barr, and J. Michael Dixon

1613 **The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer**  
Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, S. Gail Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille V. Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, and Carla M.L. van Herpen

1624 **Estrogen Receptor- $\alpha$  Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer**  
Josefine Becker, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld, and Olle Stål

1634 **A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma**  
Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates, and Tito Fojo

1642 **Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome-Encoded Minor Histocompatibility Epitopes**  
Yishai Ofran, Haesook T. Kim, Vladimir Brusic, Loren Blake, Michael Mandrell, Catherine J. Wu, Stefanie Sarantopoulos, Roberto Bellucci, Derin B. Keskin, Robert J. Soiffer, Joseph H. Antin, and Jerome Ritz

1652 | **Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma**

Thomas Puchalski, Uma Prabhakar, Qun Jiao, Birge Berns, and Hugh M. Davis

1662 | **Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma**

Christy Ralph, Eyad Elkord, Deborah J. Burt, Jackie F. O'Dwyer, Eric B. Austin, Peter L. Stern, Robert E. Hawkins, and Fiona C. Thistlethwaite

1673 | **Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma**

Howard A. Burris III, Lee S. Rosen, Caio M. Rocha-Lima, John Marshall, Suzanne Jones, Roger B. Cohen, Lori A. Kunkel, Deryk Loo, Jan Baughman, Stanford J. Stewart, and Nancy Lewis

## LETTERS TO THE EDITOR

1690 | **Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? - Letter**

Patrick Walsh

1690 | **Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? - Response**

Joseph Presti, Jr.

## CORRECTIONS

1692 | **Correction: *PIK3CA* Mutations Predict Local Recurrences in Rectal Cancer Patients**

1692 | **Correction: MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival**


## SUSCEPTIBILITY AND PREVENTION

1682 | **Implications of LINE1 Methylation for Bladder Cancer Risk in Women**

Charlotte S. Wilhelm, Karl T. Kelsey, Rondi Butler, Silvia Plaza, Luc Gagne, M. Scot Zens, Angeline S. Andrew, Steven Morris, Heather H. Nelson, Alan R. Schned, Margaret R. Karagas, and Carmen J. Marsit

## ABOUT THE COVER

The featured image is a lung adenocarcinoma stained with a novel, highly sensitive and specific antibody recognizing the ALK oncoprotein (*brown staining*) and counterstained with hematoxylin (*blue staining*). The tumor was shown to harbor a rearrangement of the *ALK* locus by genetic analysis. This assay will facilitate the routine identification of ALK-rearranged lung adenocarcinomas in clinical practice and detect lung cancers that may be responsive to ALK inhibitors. For details, see the article by Mino-Kenudson and colleagues on page 1561 of this issue.



# Clinical Cancer Research

**16 (5)**

*Clin Cancer Res* 2010;16:1345-1692.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/16/5>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/5>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.